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Objectives: The two most common breast reduction techniques presently used 
in North America are the Vertical Scar Reduction (VSR) and the Inverted T-shaped 
Reduction (ITR). A previous Randomized Controlled Trial (RCT) has shown no clear 
superiority of one over the other in terms of Health-Related Quality of Life (HRQL). 
No economic evaluation has been undertaken however to determine if the VSR 
is more cost-effective than the ITR. MethOds: 255 patients were randomized to 
either VSR or ITR immediately pre-operatively. The effectiveness of two techniques 
was measured with the HUI3. Both direct and productivity costs were captured 
parallel to the RCT. Case Report Forms (CRF) captured patient-related costs associ-
ated with the surgery. The human capital method was used to capture productiv-
ity losses. The perspectives of the Ministry of Health (MOH), the patient and the 
Society were considered Results: ITR dominated VSR under the MOH perspective 
by being slightly less costly ($3,090.06 vs. $3,106.58) and slightly more effective i.e. 
0.87 Quality Adjusted Life Years (QALY) versus 0.86 QALYs. In the societal and patient 
perspective, VSR was both less costly and less effective. At the commonly quoted 
Canadian threshold of $50,000 per QALY gained, the probability that VSR was cost-
effective was 29.3%, 68.2% and 66.9% under a MOH, patient and societal perspective 
respectively. A subgroup analysis of breast reductions of < 500 grams found that 
the VSR was more likely cost-effective. cOnclusiOns: This analysis informs us 
that the VSR is more likely than not, cost-effective from the patient and societal 
perspective but not from the MOH at a willingness-to-pay threshold of $50,000/
QALY. If, however, we were to limit the VSR for those breast reductions in which we 
expect excision of breast tissue < 500 grams per breast, then this technique is more 
likely cost-effective under all perspectives.
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Objectives: Estimate the incremental cost-effectiveness ratio (ICER) of D+T 
versus vemurafenib and dacarbazine for BRAFV600 mutation-positive MM from 
the UK NHS perspective. MethOds: A partitioned-survival model with 3 states 
(progression-free survival [PFS], post-progression survival, and death) and a 
lifetime horizon was developed. Treatment benefits were measured as gains in 
quality-adjusted life-years (QALYs). PFS and overall survival (OS) were derived 
from indirect treatment comparisons (ITCs) of D+T (from the Phase II BRF113220 
study) versus vemurafenib (BRIM-3) and dacarbazine (BREAK-3). Latest OS data 
were adjusted for confounding effects of treatment switching, permitted upon 
progression in all studies. Safety data were from aforementioned trials. Costs were 
from the literature, a physician survey, and assumptions. Costs of medications 
to the NHS (incorporating available patient-access schemes), post-study antican-
cer therapy, routine and adverse event (AE) management, treatment initiation, 
and death were included. Utility data for D+T were derived from BREAK-3, with 
adjustment for differences in response and incidence of AEs. Deterministic and 
probabilistic sensitivity analyses were performed. Results: ITCs showed D+T 
significantly improved PFS versus vemurafenib (hazard ratio [HR] 0.38; 95% CI, 
0.19–0.74) and dacarbazine (0.14; 0.08–0.28) and suggested improved OS, although 
not statistically significant (0.42; 0.09–1.97 versus vemurafenib and 0.26; 0.05–1.27 
versus dacarbazine). Treatment with D+T was associated with a gain in QALYs 
versus vemurafenib and dacarbazine. The ICER for D+T was £50,603/QALY versus 
vemurafenib and £49,804/QALY versus dacarbazine. cOnclusiOns: Based on 
results of a Phase II trial and an ITC, D+T offers improved PFS and OS versus vemu-
rafenib and dacarbazine. Further, considering NICE’s criteria for life-extending, 
end-of-life treatments, D+T may be cost-effective compared with vemurafenib, 
the NHS’s current standard of care for patients with BRAFV600 mutation-positive 
MM, although conclusions must await ongoing modelling on the basis of the Phase 
III, COMBI-D trial.
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Objectives: Muscle-invasive bladder cancer (MIBC) is a deadly disease that dis-
proportionately affects the elderly and is treated with bladder removal (i.e. radical 
cystectomy). A novel therapy utilizing chemo-radiation has demonstrated fewer 
adverse effects with comparable survival rates, with the possibility of requiring 
delayed cystectomy. The objective of this study was to examine the cost-utility of 
radical cystectomy compared to chemo-radiation in the treatment of (MIBC) among 
the elderly. MethOds: A decision-analytic model from the Medicare payer perspec-
tive followed hypothetical patients ages 65 and older with MIBC, using a 5-year 
time horizon from the start of treatment. Surgery and chemo-radiation toxicity, 
survival, and quality-of-life weights were derived from the clinical literature, and 
costs were derived from 2013 Medicare fee schedules. Sensitivity analyses were per-
formed to address the uncertainty of parameter values. Results: In the base-case 
analysis, chemo-radiation was less costly and less effective than radical cystectomy. 
Chemo-radiation resulted in a cost savings of $6,788 per patient whereas cystectomy 
resulted in additional 1.2 quality-adjusted life-years (QALY) per patient. Thus, cys-
tectomy would be preferred with an incremental cost-effectiveness ratio of $5,680 
per QALY. Therefore, at a threshold of $50,000 per QALY, chemo-radiation is not 
cost-effective when compared to radical cystectomy. Overall conclusions remained 
the same in sensitivity analyses, although the model was most dependent on the 
eases including cervical intraepithelial neoplasia grades 1 (CIN 1), grades 2 and 3 
(CIN 2/3), and cervical cancer. MethOds: A mathematical model of the transmis-
sion dynamics of HPV infection and disease for the HPV9 vaccine was calibrated 
to Japanese epidemiological data on cervical cancer. Based on global estimates, 
we attributed 70% of cervical cancer to HPV 16 and 18 for the quadrivalent vaccine 
(types 6/11/16/18: HPV4), and 20% to the five additional types in HPV9 (31, 33, 45, 
52, and 58). Other inputs were from public data sources and published literature. 
Vaccine efficacy against the 5 additional HPV types was taken from phase III trial 
results for the HPV9 vaccine. We assessed the incremental public health impact 
of HPV9 over HPV4 based on vaccinating 80% of females by age 12. Results: We 
projected that HPV9 vaccination of females could reduce the incidence of cervical 
cancer by 46% over 100 years, relative to 36% for HPV4. HPV9 vaccination relative to 
HPV4 vaccination could prevent an additional 305,000 cases of CIN1, 636,000 cases 
of CIN2/3, and 78,000 cases of cervical cancer in the Japanese population, cumula-
tive over 100 years. cOnclusiOns: Protecting the Japanese population against 
HPV infection with an HPV9 vaccination program relative to an HPV4 vaccination 
program can have significant public health benefits in addition to the benefits 
provided by HPV4 vaccination.
PCN116
COMPARING FIVE ALTERNATIVE METHODS OF BREAST RECONSTRUCTION 
SURGERY: A COST-EFFECTIVENESS ANALYSIS
Padula W.V.1, Grover R.2, Van Vliet M.3, Ridgway E.B.4
1University of Chicago, Chicago, IL, USA, 2Dartmouth College, Hanover, NH, USA, 3University of 
Southern California, Los Angeles, CA, USA, 4Dartmouth-Hitchcock Medical Center, Lebanon, NH, 
USA
Objectives: To assess cost-effectiveness of five standardized procedures for breast 
reconstruction to delineate the best reconstructive approach in the post mastectomy 
patients in the settings of non-radiated and radiated chest walls. MethOds: A decision 
tree modeled five breast reconstruction procedures from the provider perspective to 
evaluate cost-effectiveness. Procedures included autologous flaps with pedicled tissue, 
autologous flaps with free tissue, latissimus dorsi flap with breast implant, expander 
with implant exchange, and immediate implant placement. All methods were com-
pared to a do-nothing alternative. Data for model parameters was collected through a 
systematic review, and patient health utilities were calculated from an ad-hoc survey of 
reconstructive surgeons. Results were measured in cost (US $2011) per quality-adjusted 
life year (QALY). Univariate sensitivity analyses and Bayesian multivariate probalistic 
sensitivity analysis were conducted. Results: Pedicled and free autologous tissue 
reconstruction were cost-effective compared to the do-nothing alternative. Pedicled 
autologous tissue was the slightly more cost-effective of the two. The other procedures 
were not found to be cost-effective. The results were robust to a number of sensitivity 
analyses, although the margin between pedicled and free autologous tissue reconstruc-
tion is small and affected by some parameter values. cOnclusiOns: Autologous pedi-
cled tissue was slightly more cost-effective than free tissue reconstruction in radiated 
and non-radiated patients. Implant-based techniques were not cost-effective. This is 
in agreement with the growing trend at academic institutions to encourage autologous 
tissue reconstruction due to its natural recreation of the breast contour, suppleness, 
and resiliency in the setting of radiated recipient beds.
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Objectives: To the best of our knowledge, till date, US do not market any biosimilar 
for the treatment of chemotherapy induced febrile neutropenia (CIN). With Europe 
and Asia already marketing their biosimilars, it was timely to estimate the value of 
this proposed biosimilar in the US. The primary goal of this comparative technology 
assessment was to estimate the economic value by quantifying the savings offered 
by the biosimilar compared to its reference biological, filgrastim. The secondary goal 
was to highlight the clinical value of a proposed biosimilar with the help of a cost-
effectiveness analysis from a US payer perspective. The biosimilar is compared to 
filgrastim and pegfilgrastim, intended for the treatment of CIN. MethOds: A decision 
analytical model was designed and implemented using TreeAge Pro 2013 software. 
The initial cost and clinical estimates were based on a similar model published by 
Eldar-Lissai et al (2008) with modified and updated clinical estimates along with costs 
adjusted to 2013. The model was modified to include a proposed biosimilar expected 
to be released in the U.S. in 2014. Sensitivity analyses, including Monte Carlo probabil-
istic analyses, were conducted to assess the robustness of the model. Results: The 
model estimated expected costs for the three therapies to be: $3,092.41, $3,808.81, and 
$5,238.82 for biosimilar filgrastim, originator filgrastim, and pegfilgrastim respectively. 
The estimated savings of the biosimilar is estimated to be $ 716.40 per chemotherapy 
cycle and as per estimated usage, this translates to a total potential savings of $1.2 
billion by the end of 2014. The cost-effectiveness analysis resulted in an ICER of $ 
-3,766.29/day length of stay between biosimilar filgrastim and pegfilgrastim dem-
onstrating clinical value. cOnclusiOns: With the new US biosimilar legislation of 
February 2012 and filgrastim losing its patent protection in December 2013, this phar-
macoeconomic analysis is timely and significant for health policy.
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treatment was based on stage and prognostic score. Other model inputs were 
literature-derived or assumption-based. Costs and QALYs were discounted at a 
3% annual rate. One-way and probabilistic sensitivity analyses examined the rela-
tive impact of model inputs. Results: In the base case scenario 44% of patients 
received ACT using the prognostic test vs. 38% based on SoC. Total costs were 
$131,287 and $125,594 and total QALYs gained were 5.33 and 5.16 for the prognos-
tic test and SoC, respectively. The incremental cost-effectiveness ratio (ICER) for 
the prognostic test was $34,055/QALY gained. One-way sensitivity analyses indi-
cated the probability of receiving ACT for high-risk, stage Ib patients and the ACT 
treatment benefit were the largest drivers of cost-effectiveness. The probabilistic 
sensitivity analysis ICER was $44,196/QALY gained. The prognostic test was cost-
effective in 51.1% of the simulations at a willingness-to-pay threshold of $50,000/
QALY gained. cOnclusiOns: The results of this study suggest that using myPlan 
Lung Cancer to guide ACT decisions is cost-effective compared to a SoC approach 
according to globally accepted thresholds.
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Objectives: The Breast Cancer Trials of Oral Everolimus-2 (BOLERO-2) is a double-
blind, phase 3 trial that compared Everolimus plus Exemestane (n = 485) versus 
placebo plus Exemestane (n= 239). Postmenauposal women with advanced hormone 
receptor positive breast cancer (ABC) were included in the study. The trial demon-
strated that Everolimus plus Exemestane significantly prolonged progression-free 
survival (PFS). PFS as an outcome measure to compare treatment strategies for ABC 
is incomplete as it fails to account for the quality of life of patients living in that dis-
ease state. To address this issue, researchers can estimate the quality adjusted pro-
gression free survival (QAPFS) of treatments as an effectiveness measure. This study 
aims to estimate the QAPFS of the treatment arms of the BOLERO-2 trial. MethOds: 
For each treatment arm of the trial, QAPFS was estimated by multiplying the overall 
health utility weights associated with PFS (taking into consideration disutlities asso-
ciated with the adverse events of treatments) by the corresponding mean PFS time. 
Health utility data were obtained from the literature, while mean PFS times were 
estimated through the survival analysis of the reconstructed individual patient data 
of the BOLERO-2 trial. Results: Progression free survival (robust mean; (95% robust 
confidence interval) was 44.73 weeks (41.03; 48.43) for Evrolimus + Exemestane 
and 22.98 weeks (19.88; 26.08) for Placebo + Exemestane. The QAPFS (robust mean, 
(95% robust confidence interval) for the treatment arms of the trial were respec-
tively 1.67 (1.53; 1.81) for Evrolimus + Exemestane and (0.78; 1.02) for Placebo + 
Exemestane. cOnclusiOns: Using QAPFS as the outcome measure provides a 
better assessment of the benefit induced by the treatment arms of the BOLERO-2 
trial. The benefit of Everolimus + Exemestane over Placebo + Exemestane observed 
in the trial was maintained in this analysis. The estimates obtained as part of our 
analysis can be used in future cost effectiveness studies.
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mortality rate at 5 years following treatment as well as recurrence rates following 
chemo-radiation. cOnclusiOns: Cost-utility analysis comparing chemo-radiation 
to cystectomy as primary treatment for MIBC reveals that chemo-radiation is not 
cost-effective when compared to cystectomy.
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Objectives: To determine the value of different mammography screening modali-
ties from the societal context. MethOds: The Wisconsin CISNET breast cancer 
model was adapted to reflect the Canadian context (incidence, resource utilization 
and unit costs (2012 CAN$)). Predictions were made of age-specific breast cancer 
incidence for a 1960 birth cohort of 2,000,000 women for a number of screening sce-
narios varied by age bands (start at 40 or 50 years, end at 69 or 74 years), frequency 
(annual, biennial, triennial) from a societal perspective. Incremental cost-effec-
tiveness and cost-utility analyses were examined for different screening scenarios 
compared to the basecase (biennial 50 to 74 years). A 5% discount rate was used. 
Sensitivity analyses considered screening tool performance, compliance, costs and 
treatments. Results were expressed for 1,000 women alive at age 40 years. Results: 
Our model showed that all annual screening strategies were found to be more 
effective than the basecase. The most aggressive annual screening scenario (40 
to 74 years) saved the lives of 21 more women per 1,000 than the basecase at an 
additional $3,800 per woman. Our model predicted that annual screening from age 
40 to 74 years had a slightly lower incremental ratio compared to annual 40 to 49, 
biennial 50 to 74 years when compared to the basecase. Cost drivers were discount 
rate, screening frequency, utility values, treatment and sensitivity of mammogra-
phy. cOnclusiOns: The greatest single cost contributor in a screening program 
is the mammography itself. The more screens that a women receives in her life, 
the greater the financial cost to society. Because both the life savings and costs rise 
together almost linearly with the number of lifetime screens per women, the deci-
sion on how to screen is mainly related to willingness to pay and avoiding recalling 
too many women for further examinations after positive screens.
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Objectives: Analyzing the cost-effectiveness of blood cancer-related therapies 
has become more important as expensive drugs have been introduced. This study 
reviewed cost-utility analyses (CUAs) of innovative blood cancer-related interven-
tions and examined the number and methodology of studies and the cost-utility 
ratios. MethOds: We analyzed studies related to blood cancers from the Tufts 
Cost-Effectiveness Analysis Registry (www.cearegistry.org), a database including 
over 9,800 CEAs published through 2012. We focused on innovative agents and 
excluded hematopoietic stem cell transplant, symptom management, and sup-
portive care. Studies that met the inclusion criteria were categorized by four cancer 
types (chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), non-
Hodgkin’s lymphoma (NHL), and multiple myeloma (MM)) and nine treatment types 
(α interferon, alemtuzumab, bendamustine, bortezomib, dasatinib, imatinib, leno-
lidomide, rituximab alone or in combination, and thalidomide). Cost-effectiveness 
ratios were stratified by funder and cancer type. Results: Twenty-nine studies 
published from 1996-2012 (including 44 cost-effectiveness ratios) met the inclusion 
criteria. Thirty-one percent were conducted in the US. The majority (62%) used the 
health care payer perspective; 24% used the recommended societal perspective. 
Seventy-six percent were industry-funded. In 21%, economic data were collected 
alongside a clinical trial. Most ratios pertained to NHL (41%) or CML (30%) and to 
treatment with rituximab (43%), α interferon (18%), or imatinib (16%). Across cancers, 
the median ratio was highest for CML ($55,000/QALY) and lowest for NHL ($21,500/
QALY). Median ratios over time were $35,000/QALY (1996-2002), $52,000/QALY (2003-
2006), and $22,000/QALY (2007-2012). A majority of ratios (73%) fell below $50,000/
QALY, and most (86%) fell below $100,000/QALY. The median was lower for indus-
try-funded studies ($26,000/QALY) than others ($33,000/QALY). cOnclusiOns: 
Published CUAs of these blood cancer treatments demonstrate relatively good 
value. While the treatments may have high unit prices, many also seem to confer 
considerable health benefits at reasonable overall costs.
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Objectives: Limited guidance exists for health care providers deciding when to 
treat patients with adjuvant chemotherapy (ACT) in early NSCLC. This leads to 
high-risk untreated patients that could benefit, and low-risk patients who could 
avoid the toxicity and cost, from ACT. This study examined the cost-effectiveness 
of the prognostic test myPlan Lung Cancer vs. current standard of care (SoC) in 
directing ACT treatment decisions in stage I/II NSCLC. MethOds: A Markov model 
was created to examine costs (2011 US$) and effectiveness (quality-adjusted life-
years [QALYs]), from a US third-party payer perspective over a lifetime horizon. 
Patients were classified as high or low risk based on a prognostic score derived 
from stage and an expression signature based on cell cycle progression. The prob-
ability of receiving ACT was estimated from a physician survey. Benefit of ACT 
